Search
Filter Results
Displaying 571–580 of 833 for “retinal diseases”
-
Apr 12, 2021
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Development of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
May 6, 2019
ARVO 2019: Gene Therapy Clinical Trial for RP Caused by RLBP1 Mutations Ongoing in Sweden
In a Novartis lab study, mice with RLBP1 mutations had improved dark adaptation after receiving the gene therapy. The treatment remained effective after one year.
-
Age-Related Macular Degeneration
Age-related macular degeneration, or AMD, is the leading cause of blindness in people 55 and older in developed countries. The condition can lead to significant loss of central vision.
-
Jun 1, 2017
Valproic Acid's Effect Too Small in One-Year Clinical Trial
While a therapy for adRP will not emerge from the clinical trial, study investigators advanced development of a new outcome measure known as EZ Area to quickly and accurately evaluate potential therapies for RP in human studies.
-
Apr 28, 2016
ARVO 2016: Choroideremia Gene Therapy in Clinical Trial Continues to Perform Well
Five of six patients in NightStaRx’s choroideremia gene-therapy trial continue to benefit from the treatment.
-
Jun 27, 2015
VISIONS 2015 — Dr. José Sahel Receives Foundation's Most Prestigious Research Honor
For those of us supporting the drive for vision-saving treatments and cures, he’s exactly the type of person we want on our team.
-
May 10, 2024
ARVO 2024 Highlight: Positive Two-Year Results from PDE6B Gene Therapy Clinical Trial
Mutations in PDE6B are a leading cause of retinitis pigmentosa.
-
Apr 12, 2024
Phase 3 Clinical Trial of NAC Launched for RP Patients
The drug is thought to work independent of the mutated gene causing RP.
-
Mar 27, 2024
Nanoscope Plans to Apply for FDA Approval for its Optogenetic Therapy
The company reported positive two-year results for its Phase 2 clinical trial of MCO-010.
-
Jun 12, 2023
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
An emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program